Please login to the form below

Not currently logged in
Email:
Password:

Ozurdex

This page shows the latest Ozurdex news and features for those working in and with pharma, biotech and healthcare.

NICE backs Bayer's Eylea in diabetic eye condition

NICE backs Bayer's Eylea in diabetic eye condition

TheInstitute also recommends Allergan's Ozurdex in final guidance. Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema ... Meanwhile, NICE also recommended the use of Allergan's

Latest news

  • NICE recommends Ozurdex for diabetic eye condition NICE recommends Ozurdex for diabetic eye condition

    The preliminary recommendations cite the implant, marketed by Allergan as Ozurdex, as a treatment option in patients where the implant is to be used in an eye with an intraocular (pseudophakic) ... Ozurdex is injected into the eye once every six months

  • Fresh approval for Roche's Lucentis as competition heats up Fresh approval for Roche's Lucentis as competition heats up

    Roche's drug is being challenged in the market by Bayer's Eylea (aflibercept) as well as newer entrants such as Allergan's Ozurdex (intravitreal dexamethasone).

  • New eye indication for Allergan’s Ozurdex New eye indication for Allergan’s Ozurdex

    The European Commission granted marketing authorisation to Ozurdex, an eye implant that contains the corticosteroid dexamethasone, as a treatment for adults with visual impairment due to diabetic macular oedema (DMO). ... Ozurdex joins a competitive

  • Allergan will start phase III DARPin trials next year Allergan will start phase III DARPin trials next year

    On the plus side, Allergan said the FDA had approved a new indication for its intravitreal implant Ozurdex (dexamethasone), namely the treatment of diabetic macular oedema (DME) in adults who have

  • NICE against new indication for Novartis' Lucentis

    Its draft guidance concluded the ICER for Lucentis in central RVO versus Allergan's Ozurdex (dexamethasone) intravitreal implant, the currently approved treatment, was likely to be over £37, 400 per QALY ... Ozurdex was recommended by NICE earlier this

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics